Evidence-Based Pharmacologic Approaches to Reducing Suicide Risk

Individuals with severe psychiatric disorders experience a significantly elevated risk of suicide.¹ Although psychotherapy, crisis intervention, and social support are foundational, pharmacologic treatments also play a critical role. Clozapine, lithium, ketamine, and antidepressants are among the most evidence-supported agents, alongside comprehensive treatment of co-occurring psychiatric conditions.^2-4

Pharmacologic strategies can be conceptualized around 2 aims: managing acute suicidal crises and preventing chronic or recurrent suicidal behavior. Treatment decisions should reflect diagnosis, risk severity, history of suicidal behavior, and the need for rapid symptom reduction.

Management of Acute Suicidal Risk

Most presentations of suicidal ideation can be managed collaboratively in outpatient settings using safety planning, lethal means counseling, caring contacts, and suicide-focused psychotherapies such as cognitive behavioral therapy for suicide prevention (CBT-SP), dialectical behavioral therapy (DBT), and the collaborative assessment and management of suicidality (CAMS).^5-7 When ideation is accompanied by intent, planning, or other high-risk features, immediate safety becomes paramount. Hospitalization or intensified monitoring may be required to mitigate acute, short-term risk. Rapidly acting medications such as ketamine may also play an important role.

Ketamine

For patients with major depressive disorder (MDD) and severe suicidal ideation, ketamine offers rapid symptom relief. Unlike conventional antidepressants, which may take weeks to achieve therapeutic effects, ketamine can reduce depressive symptoms and suicidal ideation within hours to days.^8,9 Through N-methyl-D-aspartate (NMDA) receptor antagonism, ketamine provides a mechanistically distinct intervention. Emerging evidence suggests that its antisuicidal effects may not be entirely attributable to improvements in depressive symptoms, although the mechanisms underlying these effects remain incompletely understood.⁹ Adverse effects, including dissociation, transient hypertension, sedation, and nausea, necessitate administration in appropriately supervised clinical settings. Despite these limitations, ketamine represents an important advance in the acute management of severe suicidal ideation, although its long-term impact on suicide risk remains uncertain.

Intranasal esketamine, the S-enantiomer of racemic ketamine, is approved by the US Food and Drug Administration (FDA) for adults with treatment-resistant depression and for depressive symptoms in adults with MDD accompanied by acute suicidal ideation or behavior. However, esketamine is not approved for the prevention of suicide or reduction of suicidal behavior. Although clinical trials have demonstrated rapid improvements in depressive symptoms, evidence that esketamine reduces suicide risk or suicidal behaviors remains limited and inconsistent.¹⁰ Consequently, clinicians should view esketamine as a treatment for depressive symptoms in this population rather than as a proven suicide prevention intervention.

Other somatic treatments

Electroconvulsive therapy remains one of the most effective interventions for severe depression with suicidality, psychosis, or catatonia, often producing improvement within days.¹¹ Another promising modality currently being investigated for suicide risk reduction is transcranial magnetic stimulation.^12,13

Management of Chronic or Recurrent Suicidal Behavior

Once acute risk has stabilized, treatment shifts toward preventing recurrent suicidal behavior. Long-term management focuses on sustained treatment of underlying psychiatric disorders, ongoing monitoring, and targeted interventions for suicide risk. Historically, suicide risk was assumed to improve as the underlying psychiatric disorder improved. Increasingly, however, suicidality is conceptualized as a distinct clinical target that warrants ongoing assessment and intervention even when other psychiatric symptoms appear stable. Clozapine and lithium remain the most evidence-supported pharmacologic agents with specific antisuicidal properties.^14-17

Clozapine

For patients with schizophrenia or schizoaffective disorder who exhibit suicidal ideation or a history of attempts, clozapine is the strongest evidence-based intervention and the only medication with an FDA indication for reducing suicidal behavior in schizophrenia.¹⁴ Individuals with schizophrenia face markedly elevated suicide risk, underscoring the importance of effective preventive strategies.

The International Suicide Prevention Trial (InterSePT) demonstrated clozapine’s superiority over olanzapine in reducing suicidal behavior and suicide-related hospitalizations.¹⁴ Although its mechanism remains uncertain, clozapine’s efficacy in reducing psychosis, aggression, affective dysregulation, and functional impairment likely contributes to its protective effect.

Clozapine requires careful monitoring due to risks including agranulocytosis, myocarditis, seizures, and metabolic complications; regular hematologic and clinical surveillance is essential. Despite these demands, clozapine remains the most evidence-supported option for persistent suicidal risk in schizophrenia spectrum disorders.

Lithium

Lithium is a cornerstone treatment for bipolar disorder and is also used in selected cases of recurrent MDD. Across decades of research, lithium has consistently been associated with reduced suicide attempts and suicide mortality compared with other mood stabilizers or no maintenance treatment.^15-17 This benefit appears to extend beyond mood stabilization alone, potentially through reductions in impulsivity, aggression, emotional reactivity, and stress sensitivity.

Patients with bipolar disorder are particularly vulnerable to suicide, especially during depressive and mixed states. Lithium’s ability to reduce recurrence of mood episodes while lowering suicide risk makes it central to long-term management. Because of its narrow therapeutic index, lithium requires routine monitoring of serum levels, renal function, and thyroid function. Low-dose strategies with lithium have not been fully investigated but may have benefit for suicide prevention.

Antidepressants

Although randomized trials have not conclusively shown that antidepressants directly reduce suicidal behavior, they remain essential in treating major depression and other disorders associated with elevated suicide risk, including anxiety disorders, obsessive-compulsive disorder, posttraumatic stress disorder, and binge-eating disorder. Many studies report reductions in suicidal ideation with antidepressant treatment, and large population-based analyses associate antidepressant use with lower rates of suicidal behavior.^18-20 Notably, suicide attempt risk is often highest immediately before treatment initiation and declines after starting antidepressants or psychotherapy.²⁰

Antidepressants carry an FDA boxed warning due to a small increase in suicidal thoughts and behaviors among children, adolescents, and young adults.²¹ Subsequent analyses show no increased risk in adults older than 24 years and a protective effect in adults 65 years and older.¹⁹ The warning is intended to promote close monitoring during the early weeks of treatment or dose changes but may have had the unintended consequence of reducing identification and treatment of MDD.²² Given the substantial risks of untreated or inadequately treated depression, one of the strongest drivers of suicide risk, timely identification and effective treatment of mood disorders should be considered a core suicide prevention strategy.

Treating co-occurring psychiatric disorders

Clinicians should proactively identify and treat co-occurring psychiatric disorders that heighten suicide risk. Beyond mood disorders and schizophrenia, conditions such as posttraumatic stress disorder, anxiety disorders, substance use disorders, eating disorders, certain personality disorders, and many other serious psychiatric conditions frequently coexist with suicidal behavior¹ and can significantly amplify risk if untreated.^2-4 Pharmacologic and psychosocial interventions should be selected according to diagnostic profile and clinical need, with coordinated care across providers whenever possible.^23,24

Enhanced Clinical Management

Pharmacologic interventions are essential but rarely sufficient on their own. Enhanced clinical management integrates medication with a collaborative, patient-centered therapeutic relationship.^2,3

Collaboration should extend across the treatment team. Coordination with therapists, psychiatrists, primary care clinicians, and emergency personnel strengthens continuity of care (Figure). The principle of “never worry alone” underscores the importance of consultation when managing high-risk patients.

Flexibility is critical. Suicide risk fluctuates, particularly during crises, hospitalization, discharge, medication changes, or major stressors. Increasing contact through more frequent visits, telephone check-ins, caring contacts, or other means of outreach can help maintain safety during vulnerable periods.²⁵

Integrating pharmacologic treatment with evidence-informed psychotherapies such as CBT-SP, DBT, CAMS, and problem-solving therapy enhances coping skills and reduces emotional distress.^2,3,26,27 Combined treatment often yields better outcomes than either modality alone by addressing both biological and psychological contributors to suicidality. Family involvement, when appropriate, can improve adherence, increase monitoring for warning signs, and strengthen social support.

A structured safety plan is central to enhanced management.²⁸ Plans should include individualized coping strategies, emergency contacts, crisis resources, and steps to take when suicidal thoughts intensify. Means restriction, particularly limiting access to firearms and medications, is a key component, as reducing access to highly lethal methods consistently lowers suicide deaths.^2,17 Safety plans should be reviewed and updated regularly as circumstances change.

Concluding Thoughts

Pharmacologic interventions are a critical component of comprehensive suicide prevention. Among currently available interventions, lithium and clozapine have the strongest evidence for reducing suicidal behavior over time, whereas ketamine and perhaps esketamine address the urgent need for rapid reduction of suicidal ideation during acute crises. Clozapine remains the only FDA-approved agent specifically indicated for reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder, and lithium provides robust protection for individuals with mood disorders. Ketamine offers rapid-acting options for acute suicidal ideation, addressing a gap left by traditional antidepressants. Effective treatment of co-occurring psychiatric disorders, combined with enhanced clinical management, further reduces risk. Although no medication can eliminate suicide risk entirely, evidence-based pharmacologic treatment integrated with vigilant clinical care and psychosocial support can substantially improve outcomes and save lives.

Dr Zisook is a distinguished professor emeritus of psychiatry at UC San Diego in California.

Dr Moutier is chief medical officer at the American Foundation for Suicide Prevention, New York, NY.

References

1. Xu YE, Barron DA, Sudol K, et al. Suicidal behavior across a broad range of psychiatric disorders. Mol Psychiatry. 2023;28(7):2764-2810.

2. Moutier C. Medications and other modalities in suicide prevention. Forthcoming.

3. Zisook S, Domingues I, Compton J. Pharmacologic approaches to suicide prevention. Focus (AM Psychiatr Publ). 2023;21(2):137-144.

4. Rizk M, Mann JJ. An update on somatic treatments for suicide risk. Am J Psychiatry. 2026;183(6):382-400.

5. Brown GK, Ten Have T, Henriques GR, et al. Cognitive therapy for the prevention of suicide attempts. JAMA. 2005;294:563-570.

6. Linehan MM, Comtois KA, Murray AM, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy versus therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry. 2006;63:757-766.

7. Jobes DA. The Collaborative Assessment and Management of Suicidality (CAMS): an evolving evidence-based clinical approach to suicide risk. Suicide Life Threat Behav. 2012;42:640-653.

8. Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327-335.

9. Hochschild A, Grunebaum MF, Mann JJ. The rapid antisuicidal ideation effect of ketamine: a systematic review. Prev Med. 2021;152:106524.

10. Jollant F, Colle R, Nguyen TML, et al. Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review. Ther Adv Psychopharmacol. 2023;13:20451253231151327.

11. Li B, Zhao N, Tang N, et al. Targeting suicidal ideation in major depressive disorder with MRI-navigated Stanford accelerated intelligent neuromodulation therapy. Transl Psychiatry. 2024;14(1):21.

12. Barredo J, Berlow Y, Swearingen HR, et al. Multimodal elements of suicidality reduction after transcranial magnetic stimulation. Neuromodulation. 2021;24(5):930-937.

13. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91.

14. Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.

15. Baldessarini RJ, Tondo L. Lithium and suicidal risk. Bipolar Disord. 2022;24:3-12.

16. Mann JJ, Apter A, Bertolote J, et al. Suicide prevention strategies: a systematic review. JAMA. 2005;294:2064-2074.

17. Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69:572-579.

18. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.

19. Simon GE, Savarino J, Operskalski B, et al. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163:41-47.

20. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-339.

21. Friedman RA. Antidepressants' black-box warning—10 years later. N Engl J Med. 2014;371(18):1666-1668.

22. VA/DoD clinical practice guideline for assessment and management of patients at risk for suicide. Department of Veterans Affairs; 2019. Accessed August 19, 2026. https://www.govinfo.gov/app/details/GOVPUB-VA-PURL-gpo137181

23. Position statement on suicide prevention. American Psychiatric Association; 2023. Accessed August 19, 2026. https://www.psychiatry.org/patients-families/suicide-prevention

24. Skopp NA, Smolenski DJ, Bush NE, et al. Caring contacts for suicide prevention: a systematic review and meta-analysis. Psychol Serv. 2023;20(1):74-83.

25. Yager J, Feinstein RE. General psychiatric management for suicidal patients, with remarks on chronicity: contending with the angel of death. J Nerv Ment Dis. 2017;205(6):419-426.

26. Yager J, Feinstein RE. A common factors approach to psychotherapy with chronically suicidal patients: wrestling with the angel of death. Psychiatry. 2017;80(3):207-220.

27. Stanley B, Brown GK, Brenner LA, et al. Comparison of the Safety Planning Intervention with follow-up vs usual care of suicidal patients treated in the emergency department. JAMA Psychiatry. 2018;75:894-900.

28. Hawton K, Knipe D, Pirkis J. Restriction of access to means used for suicide. Lancet Public Health. 2024;9(10):e796-e801.